Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hirohiko Uchida"'
Autor:
Sarah L. Vowler, Makoto Nishio, Hiroshi Sakai, Tomonori Hirashima, Katsuyuki Kiura, Fumio Imamura, Tetsuya Mitsudomi, Kazuo Kasahara, Toyoaki Hida, Miyako Satouchi, Hirohiko Uchida, Isamu Okamoto, Terufumi Kato
Publikováno v:
Cancer Science
Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard of care for non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations. However, almost all patients develop resistance after approximately 1 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dbaffb11317bd0c67731dcc6dcd1609
http://europepmc.org/articles/PMC6726692
http://europepmc.org/articles/PMC6726692
Autor:
Fumio Imamura, Suresh S. Ramalingam, Hirohiko Uchida, Kazuhiko Nakagawa, Andrew Walding, Yuichiro Ohe, Naoyuki Nogami, Sarah L. Vowler, Rachel Hodge, Takayasu Kurata, Isamu Okamoto, Shunichi Sugawara, Terufumi Kato
Publikováno v:
Japanese Journal of Clinical Oncology
In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-of-care (gefitinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced or metastatic NSCLC.
Backgro
Backgro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7170552ae331f96ee6df534d92993632
https://doi.org/10.1093/jjco/hyy179
https://doi.org/10.1093/jjco/hyy179
Autor:
Nobuyuki Katakami, Rachel Hodge, Masaharu Shinkai, Terufumi Kato, Isamu Okamoto, Toyoaki Hida, Hiroaki Akamatsu, Fumio Imamura, Hirohiko Uchida, Young Hak Kim
Publikováno v:
Cancer Science. 109:1930-1938
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b825f3ef9fe488a8d14bfc9de73bd9c7
https://doi.org/10.1111/cas.13623
https://doi.org/10.1111/cas.13623
Autor:
Hirohiko Uchida, Nobuyuki Katakami, Mireille Cantarini, Kiyotaka Yoh, Naoyuki Nogami, Kazuo Kasahara, Isamu Okamoto, Toshiaki Takahashi, Rachel Hodge, Katsuyuki Kiura
Publikováno v:
Cancer Science
Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b432b5033b8de432a112ac16efce29
https://doi.org/10.1111/cas.13511
https://doi.org/10.1111/cas.13511
Autor:
Yutaka, Nishiwaki, Seiji, Yano, Tomohide, Tamura, Kazuhiko, Nakagawa, Shinzoh, Kudoh, Takeshi, Horai, Kazumasa, Noda, Ichiro, Takata, Koshiro, Watanabe, Hideo, Saka, Koji, Takeda, Fumio, Imamura, Kaoru, Matsui, Nobuyuki, Katakami, Akira, Yokoyama, Yoshiyuki, Sawa, Minoru, Takada, Katsuyuki, Kiura, Takahiko, Sugiura, Masahiro, Fukuoka, Hirohiko, Uchida
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 31(4)
The multinational, multi-institutional clinical Phase II trial of gefitinib monotherapy, IDEAL (IRESSA Dose Evaluation in Advanced Lung Cancer) 1, included Japanese and non-Japanese patients with advanced non-small-cell lung cancer (NSCLC) pretreated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a53d607aa47803d622e7ec61ebc353b
https://pubmed.ncbi.nlm.nih.gov/15114701
https://pubmed.ncbi.nlm.nih.gov/15114701
Publikováno v:
NIPPON SUISAN GAKKAISHI. 46:1151-1158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37c69025e34bf53acc740b1eb13bae2f
https://doi.org/10.2331/suisan.46.1151
https://doi.org/10.2331/suisan.46.1151